Table 1.
Participants’ classification criteria, attending to CSF biomarkers and neuropsychological assessment.
| Clinical Evaluation | Classification of Participants | ||||
|---|---|---|---|---|---|
| Healthy | MCI-AD | MD-AD | AD-AD | Non-AD | |
| β-Amyloid-42 (pg·mL−1) | >725 | <725 | <725 | <725 | >725 |
| t-tau (pg·mL−1) | <485 | >485 | >485 | >485 | <485 |
| p-tau (pg·mL−1) | <56 | >56 | >56 | >56 | <56 |
| ADCS-ADL-MCI | >44 | <44 | <44 | <44 | <44 |
| CDR | 0 | ≤0.5 | ≤1 | ≥2 | ≤1 |
| FAQ | <9 | <9 | >9 | >9 | >9 |
| MMSE | ≥27 | ≤27 | ≤27 | ≤27 | ≤27 |
| RBANS.DM | ≥85 | ≤85 | ≤85 | ≤85 | ≤85 |
t-tau: total tau; p-tau: phosphorylated tau; ADCS-ADL-MACI: AD Co-operative Study ADL Scale for Mild Cognitive Impairment; CDR: Clinical Dementia Rating; FAQ: Functionality Assessment Questionnaire; MMSE: Mini-Mental State Examination; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status (DM: delayed memory; A: attention; L: learning; VC: visuospatial/constructional; IM: immediate memory).